Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients

Simple item page
dc.contributor.authorYan, Yi
dc.contributor.authorSkliris, George P
dc.contributor.authorPenner, Carla
dc.contributor.authorChooniedass-Kothari, Shilpa
dc.contributor.authorCooper, Charlton
dc.contributor.authorNugent, Zoann
dc.contributor.authorBlanchard, Anne
dc.contributor.authorWatson, Peter H
dc.contributor.authorMyal, Yvonne
dc.contributor.authorMurphy, Leigh C
dc.contributor.authorLeygue, Etienne
dc.date.accessioned2013-04-15T11:06:00Z
dc.date.available2013-04-15T11:06:00Z
dc.date.issued2009-09-09
dc.date.updated2013-04-15T11:06:00Z
dc.description.abstractAbstract Introduction The steroid receptor RNA activator is a functional RNA suspected to participate in the mechanisms underlying breast tumor progression. This RNA is also able to encode for a protein, Steroid Receptor RNA Activator Protein (SRAP), whose exact function remains to be determined. Our aim was to assess, in a large breast cancer cohort, whether levels of this protein could be associated with outcome or established clinical parameters. Methods Following antibody validation, SRAP expression was assessed by tissue-microarray (TMA) analysis of 372 breast tumors. Clinical follow-up and parameters such as steroid receptor and node status were available for all the corresponding cases. Immunohistochemical scores were independently determined by three investigators and averaged. Statistical analyses were performed using standard univariate and multivariate tests. Results SRAP levels were significantly (Mann-Whitney rank sum test, P < 0.05) higher in estrogen receptor-alpha positive (ER+, n = 271), in progesterone receptor positive (PR+, n = 257) and in older patients (age > 64 years, n = 182). When considering ER+ tumors, PR+ tumors, or younger patients (≤ 64 years), cases with high SRAP expression had a significantly (Mantel-Cox test, P < 0.05) worse breast cancer specific survival (BCSS) than those with low SRAP levels. SRAP also appeared as a very powerful indicator of poor prognostic for BCSS in the subset of ER+, node negative and young breast cancer patients (Cox regression analysis, n = 60, BCSS Hazard Ratio = 8.61, P < 0.006). Conclusions Our data suggest that SRAP levels might provide additional information on potential risk of recurrence and negative outcome in a specific set of patients with otherwise good prognosis when considering only estrogen receptor and nodal status.
dc.description.versionPeer Reviewed
dc.identifier.citationBreast Cancer Research. 2009 Sep 09;11(5):R67
dc.identifier.doihttp://dx.doi.org/10.1186/bcr2359
dc.identifier.urihttp://hdl.handle.net/1993/18864
dc.language.rfc3066en
dc.rightsopen accessen_US
dc.rights.holderYi Yan et al.; licensee BioMed Central Ltd.
dc.titleSteroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
bcr2359.xml
Size:
126.74 KB
Format:
Extensible Markup Language
Description:
Download
Thumbnail Image
Name:
bcr2359.pdf
Size:
1.65 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works